Table 5.
Summary of ongoing registered clinical trials of NMDAR-based therapies in neurological diseases.
| NMDAR-Based Drug | Neurological Disease | Primary Outcomes | Identifier | |
|---|---|---|---|---|
| NMDAR Antagonists | Amantadine | PD | • Effect on dyskinesias in PD vs PLC | UMIN000000780 |
| • Effect on levodopa-induced dyskinesia vs PLC | NCT00632762 | |||
|
| ||||
| FTLD | • Efficacy in FTLD vs PLC | NCT00127114 | ||
|
| ||||
| Dextromethorphan | Rett syndrome | • Effect on EEG abnormalities vs PLC | NCT00593957 | |
| • Effect on EEG abnormalities vs DNP | NCT00069550 | |||
|
| ||||
| Ketamine | CRPS | • Pain relief vs PLC | NCT00579085 | |
|
| ||||
| Cancer NeP | • Pain relief with standard management vs standard management alone | ISRCTN49116945 | ||
| • Pain relief with opioids vs opioids alone | NCT00484484 | |||
| • Intranasal ketamine for pain vs PLC | NCT00492388 | |||
| • Subcutaneous ketamine for pain vs PLC | ACTRN12607000501448 | |||
|
| ||||
| Chronic post-op NeP | • Effect on pain after major back surgery vs PLC | NCT00618423 | ||
| • Effect on pain after thoracotomy vs PLC | NCT00313378 | |||
| • Effect on pain after mastectomy vs PLC | NCT00129597 | |||
|
| ||||
| Memantine | AD | • Effect on MRS parameters in mild to moderate AD vs DNP | NCT00505167 | |
| • Effect on MRS parameters with DNP, RIV or GAL | NCT00551161 | |||
| • Effect on behaviour in severe AD | NCT00401167 | |||
| • Effect on agitation in moderate to severe AD | NCT00371059 | |||
| • Effect on agitation and ADLs vs neuroleptic | ISRCTN68407918 | |||
| • Efficacy in moderate to severe AD (MMT vs DNP vs MMT+DNP) | ISRCTN49545035 | |||
|
| ||||
| FTLD | • Effect on FDG-PET parameters | NCT00594737 | ||
| • Efficacy in FTLD vs PLC | NCT00200538, NCT00545974 | |||
|
| ||||
| DLB/PDD | • Effect on cognition in PDD vs PLC | NCT00294554 | ||
| • Efficacy in DLB and PDD vs PLC | NCT00630500, ISRCTN89624516 | |||
|
| ||||
| PD | • Effect on non-motor symptoms vs PLC | NCT00646204 | ||
|
| ||||
| HD | • Effect on cognition and behaviour in HD | NCT00652457 | ||
|
| ||||
| TBI | • Effect on cognition vs PLC | NCT00462228 | ||
|
| ||||
| ALS | • Efficacy in ALS with various doses | NCT00409721 | ||
| • Efficacy in ALS vs PLC | NCT00353665 | |||
|
| ||||
| Neramexane | AD | • Efficacy in moderate to severe AD vs PLC | NCT00090116 | |
|
| ||||
| Drugs with Multiple MOAs | Dimebon | AD | • Efficacy in mild to moderate AD vs PLC | NCT00377715 |
|
| ||||
| HD | • Efficacy in HD vs PLC | NCT00497159 | ||
|
| ||||
| Riluzole | ALS | • Decline in respiratory function with arundic acid vs with PLC | NCT00403104 | |
|
| ||||
| MS | • Effect on MRI parameters combined with Avonex in CIS | NCT00501943 | ||
|
| ||||
| Glycine Site Agonist | D-Cycloserine | Schizophrenia | • Effect on antipsychotic-resistant symptoms | UMIN000000468 |
|
| ||||
| Autism | • Safety and efficacy in children with autism vs PLC | NCT00198120 | ||
| • Efficacy as add-on to aripiprazole | NCT00198107 | |||
|
| ||||
| EAAT Upregulator | Ceftriaxone | ALS | • Efficacy in ALS vs PLC | NCT00349622 |
|
| ||||
| Signalling Protein Modulators | Bryostatin-1 | AD | • Efficacy in mild to moderate AD vs PLC | NCT00606164 |
|
| ||||
| Nefiracetam | AD | • Efficacy in mild to moderate AD vs PLC | NCT00001933 | |
AD=Alzheimer’s disease. ALS=amyotrophic lateral sclerosis. CIS=clinically isolated syndrome. CRPS=Complex regional pain syndrome. DLB=dementia with Lewy bodies. DNP=donepezil. EAAT=excitatory amino acid transporter. FTLD=frontotemporal lobar degeneration. HD=Huntington’s disease. MOAs=mechanisms of action. MS=multiple sclerosis. NeP=neuropathic pain. PD=Parkinson’s disease. PDD=Parkinson’s disease dementia. PLC=placebo. TBI=traumatic brain injury.